Neurocrine Biosciences, Inc. Forecast, price target & analysts
Neurocrine Biosciences, Inc. Target price 2025 - Analyst rating & recommendation
Neurocrine Biosciences, Inc. Classifications & Recommendation:
Neurocrine Biosciences, Inc. Price Target
| Target Price | $166.92 |
| Price | $117.51 |
| Potential |
42.05%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Neurocrine Biosciences, Inc. 2026 .
The average Neurocrine Biosciences, Inc. target price is $166.92.
This is
42.05%
register free of charge
$192.00
63.39%
register free of charge
$138.00
17.44%
register free of charge
|
|
| A rating was issued by 28 analysts: 22 Analysts recommend Neurocrine Biosciences, Inc. to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2026 of
42.05%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.36 | 2.68 |
| 24.81% | 14.00% | |
| EBITDA Margin | 26.50% | 23.50% |
| 20.17% | 11.31% | |
| Net Margin | 13.88% | 15.75% |
| 6.72% | 13.43% |
24 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2025. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.29 | 4.26 |
| 33.20% | 29.48% | |
| P/E | 27.62 | |
| EV/Sales | 4.15 |
20 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Neurocrine Biosciences, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
Current Neurocrine Biosciences, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 24 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 21 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 10 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Feb 10 2025 |
| B of A Securities | Locked ➜ Locked | Locked | Feb 07 2025 |
| Wedbush | Locked ➜ Locked | Locked | Feb 07 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 10 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Feb 10 2025 |
|
Locked
B of A Securities: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
Wedbush: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
